Switching from fulvestrant and kisqali to imlunestrant and kisqali for metastatic breast cancer, what should I know

Understanding Your Treatment Switch

This is an important change in your endocrine therapy regimen, and I'm glad you're asking questions about it. Let me explain what's happening and what you should know.

What You're Switching Between

Fulvestrant (Faslodex) and elacestrant (Orserdu) are both in a drug class called SERDs (Selective Estrogen Receptor Degraders). According to the NCCN Guidelines for Metastatic Breast Cancer, these medications work by destroying estrogen receptors on hormone receptor-positive cancer cells, preventing the cancer from using hormones to grow.

Your Kisqali (ribociclib) is staying the same—it's a CDK4/6 inhibitor that works alongside endocrine therapy to slow cancer cell growth.

Why Doctors Make This Switch

When patients move from fulvestrant to elacestrant, oncologists typically consider:

• Treatment response: How well your cancer responded to the first regimen
• Side effects: Whether you experienced tolerability issues with fulvestrant (which requires injections)
• Disease progression: Whether imaging showed the cancer was stable, responding, or progressing
• Emerging evidence: Newer data about how different SERDs perform in specific situations

Elacestrant is an oral medication (taken by mouth), whereas fulvestrant requires intramuscular injections, which may affect convenience and tolerability.

Key Things to Monitor

During this transition, watch for:

• Any new side effects as your body adjusts to elacestrant
• Changes in how you feel compared to fulvestrant
• Any gastrointestinal symptoms (elacestrant can affect digestion)
• Continued monitoring of your cancer markers and imaging

Important considerations:

• Both medications suppress estrogen, which affects fertility and can cause menopausal symptoms
• You'll continue regular blood work and imaging to assess how well the combination is working
• The timing of when you stop fulvestrant and start elacestrant matters—ask your team about the exact transition plan

Questions to Ask Your Oncology Team

1. Why specifically are you recommending elacestrant over continuing fulvestrant? (This helps you understand the clinical reasoning for YOUR case)

2. How will we transition between these medications? (Do I stop fulvestrant immediately, or is there an overlap period?)

3. What side effects should I expect with elacestrant that might differ from fulvestrant?

4. How will you monitor whether this new combination is working? (What tests, how often, what results indicate good response?)

5. If this combination doesn't work as well, what would be the next treatment option?

Important Context

According to the NCCN Guidelines for Metastatic Breast Cancer, endocrine therapy combined with CDK4/6 inhibitors like Kisqali is a standard approach for hormone receptor-positive metastatic breast cancer. Your care team is adjusting within this proven framework based on your individual response and tolerability.

The fact that you're staying on Kisqali while switching the SERD component suggests your doctor believes this combination addresses your specific situation better than your previous regimen.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.